Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KalVista Wins £2.4m Biomedical Catalyst Grant

Published: Tuesday, November 06, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Grant to further develop oral plasma kallikrein inhibitors as a treatment for diabetic macular edema.

KalVista Pharmaceuticals has announced that it has won a £2.4 million grant from the Technology Strategy Board under the UK Government’s £180 million Biomedical Catalyst funding initiative for research and development in the life sciences.

KalVista will use the new funding to accelerate the development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME), the leading cause of working-age adult blindness.

The current first-line treatment for DME is laser or Vascular Endothelial Growth Factor (VEGF) inhibitors but there is still no National Institute for Health and Clinical Excellence (NICE) approved pharmacological therapy available in the UK so there remains a medical and economic need for these patients.

Plasma kallikrein is an enzyme recently shown to be elevated in the vitreous of DME patients and to cause excessive vascular permeability in models of diabetes, suggesting its potential as a novel VEGF-independent target for the treatment of DME.

The Biomedical Catalyst grant will allow KalVista to complete pre-clinical development of oral plasma kallikrein inhibitors identified by the Company and prepare a drug candidate ready for Phase I clinical development.

“We are very pleased to have secured Biomedical Catalyst funding for the development of an oral plasma kallikrein inhibitor for DME,” said Andrew Crockett, KalVista’s CEO.

Crockett continued, “It is a recognition of the potential of our approach and the expertise of our team and will allow us to bring to the clinic more rapidly a new treatment that we hope will ultimately improve outcomes for patients with what is a very serious complication in diabetes.

“The oral programme will run alongside our $2.2 million collaboration with the JDRF, the leading global organization focused on type 1 diabetes (T1D) research, for the development of an intravitreal (IVT) injectable form of plasma kallikrein inhibitor. That collaboration is progressing well with first in human trials planned for next year. We look forward to similarly rapid progress under the Biomedical Catalyst grant.”

KalVista’s oral and intravitreal injection plasma kallikrein inhibitor programmes both draw on the Company’s established leadership position and expertise with this target class.

While both routes of administration offer potential benefits to patients, a successful oral drug would offer a novel delivery approach for better patient acceptability and the possibility of earlier treatment of the disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KalVista Announces Start of Clinical Development for Novel Treatment for DME
Phase I trial of plasma kallikrein inhibitor to be conducted in the US.
Thursday, August 21, 2014
New EU Consortium Focused on Discovery and Development of Novel Eye Therapeutics
Consortium supported by EU Seventh Framework Programme.
Monday, October 14, 2013
Scientific News
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!